Yang et al., 2010 - Google Patents

Silencing Nogo‐A promotes functional recovery in demyelinating disease

Yang et al., 2010

View HTML
Document ID
106100099460255605
Author
Yang Y
Liu Y
Wei P
Peng H
Winger R
Hussain R
Ben L
Cravens P
Gocke A
Puttaparthi K
Racke M
McTigue D
Lovett‐Racke A
Publication year
Publication venue
Annals of neurology

External Links

Snippet

Objective To determine if suppressing Nogo‐A, an axonal inhibitory protein, will promote functional recovery in a murine model of multiple sclerosis (MS). Methods A small interfering RNA was developed to specifically suppress Nogo‐A (siRNA‐NogoA). The siRNA‐NogoA …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Yang et al. Silencing Nogo‐A promotes functional recovery in demyelinating disease
Sonar et al. IFN‐γ promotes transendothelial migration of CD4+ T cells across the blood–brain barrier
Machado-Santos et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells
de Rivero Vaccari et al. P2X4 receptors influence inflammasome activation after spinal cord injury
Wang et al. Toll‐like receptor 2/4 heterodimer mediates inflammatory injury in intracerebral hemorrhage
Ochs et al. Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity
Flach et al. Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease
Williams et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis
Hinson et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica
von Büdingen et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets
Ji et al. Obesity promotes EAE through IL-6 and CCL-2-mediated T cells infiltration
Yu et al. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis
Ishihara et al. Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis
Li et al. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity
Yang et al. Inhibition of interferon regulatory factor 4 suppresses Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis
Meyer Zu Horste et al. Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies
Koga et al. Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris
Lalor et al. T h1‐mediated experimental autoimmune encephalomyelitis is CXCR 3 independent
Aliu et al. Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen‐specific glycopolymer
TWI572358B (en) Alpha-enolase specific antibodies and methods of use in immune diseases
Chen et al. Small-molecule antagonist of VLA-4 (GW559090) attenuated neuro-inflammation by targeting Th17 cell trafficking across the blood-retinal barrier in experimental autoimmune uveitis
Rathod et al. Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice
Lühder et al. Laquinimod enhances central nervous system barrier functions
Velázquez et al. Sialomucin CD 43 regulates T helper type 17 cell intercellular adhesion molecule 1 dependent adhesion, apical migration and transendothelial migration
Asashima et al. The Anergy Induction of M3 Muscarinic Acetylcholine Receptor–Reactive CD4+ T Cells Suppresses Experimental Sialadenitis‐like Sjögren's Syndrome